Company Completed Phase 1 Interim Data Analysis for Lead Asset, RE104, Which Showed Strong Safety and Tolerability with Differentiated Profile; Final Data Anticipated in Mid-2023 Continued to Strengthen Executive Team; Named Dr. Robert Alexander as Chief Medical Officer At December 31, 2022, Reunion Held CAD $32.4 Million in Cash and Cash Equivalents TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE)…


Previous articleSilo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
Next articleDelix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate Drug Discovery and Translatability